Project description DEENESFRITPL Predicting the outcome of liver transplantation Liver transplantation is sometimes the only option for patients with end-stage liver failure caused by cirrhosis, alcohol-induced disease or non-alcoholic fatty liver disease, or for those who suffer from liver cancer. To meet the limited availability in organs, patients undergo an eligibility assessment and must meet specific clinical criteria to enter the transplant waiting list. The EU-funded HepatoPredict project has developed a predictive tool that offers improved decision support to clinicians for patient selection. The tool combines molecular data as well as clinical parameters to compute the prognostic outcome of liver transplantation. Results so far show a success rate of 82 %, offering a powerful means of supporting this procedure. Show the project objective Hide the project objective Objective Hepatocellular carcinoma (HCC) is a leading cause of cancer related mortality world-wide. The best curative treatment option is liver transplantation. The need for liver transplants for HCC by far exceeds the number of available organs, so stringent selection criteria are of paramount importance in order to ensure that the best candidates are selected for the procedure. So far, clinicians have to rely only on clinical variables to select transplant candidates for liver transplantation. The current criteria used (MILAN criteria) limits transplant to patients within specific parameters as tumour number and diameter, clearly related to disease and tumour biological behavior, but can only act as surrogate markers of tumour stage and biology. Hence, it is not possible to predict which patients outside the Milan criteria that would have a favourable prognosis. On this background, it is of outmost importance to gain access to better predictive tools that can provide decision support in selection for these patients. In response to this challenge, Ophiomics has developed a powerful predictive tool (HepatoPredict) based on molecular signature and clinical parameters, rather than only clinical variables. We can predict the good outcome of the intervention with a successful-curative rate of 82%, improving the Milan criteria one (67%). Unsuccessful liver transplantation will be avoided and, as a consequence, better survival rate and more saved lives will be achieved. Upon 5 years after the completion of the project, HepatoPredict will boost the growth of our company generating additional 15 FTEs and a ROI of 10.49. With the help of SME instrument, Ophiomics aims to complete the clinical validation and product optimization so that it can be commercialized across European markets first, and global markets later on, improving the quality of care of healthcare systems worldwide as well as the HCC patient´s quality of life. Fields of science medical and health sciencesclinical medicineoncologyliver cancersocial sciencessociologydemographymortalitymedical and health sciencesclinical medicinetransplantation Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator OPHIOMICS - INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA SA Net EU contribution € 50 000,00 Address RUA CUPERTINO DE MIRANDA N9 LOTE 8 POLO TECNOLOGICAO DE LISBOA 1600 513 Lisboa Portugal See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
